concept

RB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2519Connections

26Hypotheses

0Analyses

50Outgoing

50Incoming

2Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	RB
Linked Hypotheses	5 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    RB["RB"]
    style RB fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    RB -->|"interacts"| Als["Als"]
    RB -.->|"inhibits"| Atherosclerosis["Atherosclerosis"]
    RB -->|"activates"| Dementia["Dementia"]
    RB -->|"activates"| Alzheimer["Alzheimer"]
    RB -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    RB -->|"interacts"| Parkinson["Parkinson"]
    MTOR([MTOR]) -.->|"inhibits"| RB
    AMPK([AMPK]) -->|"interacts"| RB
    ABCA1([ABCA1]) -->|"interacts"| RB
    P2RY12([P2RY12]) -.->|"inhibits"| RB
    ABCG1([ABCG1]) -->|"interacts"| RB
    ALS([ALS]) -->|"interacts"| RB
    MAO([MAO]) -.->|"inhibits"| RB
    ULK1([ULK1]) -->|"interacts"| RB
    ATP([ATP]) -->|"interacts"| RB
    ACTB([ACTB]) -->|"interacts"| RB

Outgoing (446)

Target	Relation	Type	Str
Vascular Dementia	activates	disease	0.60
Huntington	associated_with	disease	0.60
Traumatic Brain Injury	activates	disease	0.60
Fibrosis	inhibits	disease	0.60
Ferroptosis	therapeutic_target	disease	0.60
Pyroptosis	regulates	disease	0.60
Pyroptosis	inhibits	disease	0.60
Diabetes	inhibits	disease	0.60
Ischemia	regulates	disease	0.60
Ferroptosis	interacts_with	disease	0.60
Senescence	activates	disease	0.60
Aging	protects_against	disease	0.60
Atherosclerosis	inhibits	disease	0.60
Neuroinflammation	protects_against	disease	0.60
Multiple Sclerosis	causes	disease	0.60
Multiple Sclerosis	inhibits	disease	0.60
Stroke	causes	disease	0.60
Bipolar	therapeutic_target	disease	0.60
Depression	therapeutic_target	disease	0.60
Ischemia	expressed_in	disease	0.60
Parkinson	inhibits	disease	0.60
Autism	regulates	disease	0.60
Autism	expressed_in	disease	0.60
Aging	inhibits	disease	0.60
Senescence	therapeutic_target	disease	0.60
Fibrosis	therapeutic_target	disease	0.60
Tauopathy	activates	disease	0.60
Aging	expressed_in	disease	0.60
Dementia	expressed_in	disease	0.60
Traumatic Brain Injury	causes	disease	0.60
Epilepsy	activates	disease	0.60
Tauopathy	expressed_in	disease	0.60
Cancer	activates	disease	0.60
Huntington	therapeutic_target	disease	0.60
Neurodegeneration	expressed_in	disease	0.60
Traumatic Brain Injury	inhibits	disease	0.60
Senescence	associated_with	disease	0.60
Autism	associated_with	disease	0.60
Cancer	inhibits	disease	0.60
Neuroinflammation	interacts_with	disease	0.60
Stroke	expressed_in	disease	0.60
Fibrosis	causes	disease	0.60
Cancer	causes	disease	0.60
Obesity	interacts_with	disease	0.60
Depression	interacts_with	disease	0.60
Neuropathy	associated_with	disease	0.60
Als	interacts_with	disease	0.60
Pyroptosis	causes	disease	0.60
Glioblastoma	regulates	disease	0.60
Huntington	expressed_in	disease	0.60

Incoming (2073)

Source	Relation	Type	Str
JUN	expressed_in	gene	0.60
TUBB	regulates	gene	0.60
SLC6A3	regulates	gene	0.60
SNCA	regulates	gene	0.60
TUBB4B	regulates	gene	0.60
TUBB3	regulates	gene	0.60
NDUFA9	regulates	gene	0.60
ABCA1	therapeutic_target	gene	0.60
JUN	therapeutic_target	gene	0.60
APOE4	activates	gene	0.60
TAU	activates	gene	0.60
APOE	activates	gene	0.60
APOE4	associated_with	gene	0.60
ST6GAL1	regulates	gene	0.60
FUT8	regulates	gene	0.60
BACE1	therapeutic_target	gene	0.60
EGFR	therapeutic_target	gene	0.60
APP	therapeutic_target	gene	0.60
FOXO1	activates	gene	0.60
FOXO4	activates	gene	0.60
AKT	activates	gene	0.60
PI3K	activates	gene	0.60
FOXO1	regulates	gene	0.60
CCL4	regulates	gene	0.60
MTOR	associated_with	gene	0.60
BECN1	associated_with	gene	0.60
ULK1	associated_with	gene	0.60
VAMP8	associated_with	gene	0.60
TFEB	associated_with	gene	0.60
GAPDH	associated_with	gene	0.60
NBR1	associated_with	gene	0.60
RB1	associated_with	gene	0.60
HDAC6	associated_with	gene	0.60
OPTINEURIN	associated_with	gene	0.60
OPTN	associated_with	gene	0.60
WIPI2	associated_with	gene	0.60
STX17	associated_with	gene	0.60
SIRT1	associated_with	gene	0.60
LAMP2A	associated_with	gene	0.60
HSP70	associated_with	gene	0.60
LC3	associated_with	gene	0.60
SNAP29	associated_with	gene	0.60
PRKN	associated_with	gene	0.60
GABARAP	associated_with	gene	0.60
RAB2A	associated_with	gene	0.60
RB1CC1	associated_with	gene	0.60
LAMP2	associated_with	gene	0.60
DNM1L	associated_with	gene	0.60
VAMP7	associated_with	gene	0.60
NPTX2	biomarker_for	gene	0.60

Targeting Hypotheses (26)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ	0.738	neuroinflammation	How do B cells mechanistically orchestra
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Ne	0.670	neurodegeneration	What are the specific molecular mechanis

Vascular mural cell degeneration precedes and exacerbates pa	0.661	alzheimers	SEA-AD Single-Cell Analysis: Cell-Type V
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Non-Neuronal Transcriptional Changes Pre
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.597	neuroinflammation	What molecular mechanisms determine whet
Parthenolide perturbs adenosine transport or metabolism upst	0.506	neuropharmacology	How does parthenolide specifically modul
REV-ERB Agonist Microglial Deactivation	0.455	chronobiology	Can circadian interventions reverse micr
Phosphatidylserine Decarboxylase (PISD) Restoration to Corre	0.342	lipidomics	Lipid metabolism dysregulation in Alzhei
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacolog	0.308	metabolomics	Metabolomic signatures of neurodegenerat
Compensatory RBP Expression Therapy	0.000	-	RNA binding protein dysregulation across
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Proteostasis Network Activation for RBPs	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A
Irisin effects on angiogenesis in human endothelial cells	exploratory	bone fracture	0.900	0.00	human umbilical vein endotheli	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990]	Keller A	Annual review of physiology	2026
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811]	Wang Y, Zhang Z, Cao L, Huang S, Huang X	J Ethnopharmacol	2026
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710]	Yang X, Xiao JH, Li X, Liu RM, Yuan Q	J Ethnopharmacol	2026
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296]	Maier AD, Laurentiussen CO, Michaelsen S	Acta Neuropathol Commun	2026
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797]	Prabhudesai S, Thirugnanam K, Song X, Ya	Life Sci Alliance	2026
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860]	Li J, Li A, Ye C, Zhang L, Jiang M et al	Mol Neurodegener	2026
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210]	Sun F, Zhao Y, Do J, Cheng P, Li E et al	Nat Commun	2026
Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129]	Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu	Clinical & experimental ophtha	2026

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning RB in their description or question text

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro